AI drug-discovery became the focus of a new partnership announced by LenioBio GmbH and Twist Bioscience Corporation on May 8 in Düsseldorf, Germany. The companies said they will combine LenioBio’s ALiCE® cell-free protein expression platform with Twist’s DNA manufacturing and automation systems. The goal centers on speeding up protein expression services and reducing delays in experimental testing workflows tied to AI-driven biologic development.
🔑 Key Highlights
- LenioBio and Twist Bioscience announced a collaboration agreement
- ALiCE® platform enables protein production within 24 hours
- Collaboration targets faster AI-driven protein design iteration cycles
- Twist will add cell-free protein expression capabilities
- Experimental data will feed back into AI models faster
The collaboration is designed to improve the design-build-test process used in protein and antibody discovery. LenioBio said the integrated setup can return experimental findings to customers’ and partners’ AI systems more quickly. According to the companies, this tighter laboratory feedback process could help AI models make updated design decisions using fresh experimental results rather than waiting through longer expression timelines tied to conventional bottlenecks.
LenioBio Chief Executive André Goerke said AI systems can generate designs for biologic drug molecules, but laboratory outcomes do not always match computational expectations. He said the partnership combines automated manufacturing and characterization capabilities from Twist with the ALiCE® system to generate real-world molecular data at higher speed. The companies described this process as a tighter laboratory-in-the-loop cycle where experimental evidence continuously informs the next stage of computational design.
The companies also emphasized the role of iteration speed and biology-native data quality in AI-led protein and antibody development. LenioBio said the ALiCE® platform can generate full-length, functional proteins within 24 hours while reducing delays between computational design and wet-lab testing. The platform also supports complex molecules with eukaryotic properties that other cell-free systems may struggle to produce, according to the announcement. Twist said the collaboration will expand and complement its current protein expression capabilities.
Emily M. Leproust, chief executive and co-founder of Twist Bioscience, described AI-led antibody development as a rapidly growing area within biologics research. She said the company had already expanded its characterization services for customers working in AI-enabled drug discovery and now plans to extend those capabilities further through the addition of cell-free protein expression. The collaboration positions both companies around faster experimental cycles intended to improve model performance and decision-making workflows.
📊 What This Means (Our Analysis)
The partnership highlights how AI development in biologics increasingly depends on laboratory speed rather than software capability alone. Faster experimental validation can tighten the connection between computational design and physical testing, helping researchers refine models using real biological outcomes instead of slower feedback loops.
This collaboration also reflects growing demand for integrated systems that combine automation, protein expression, and AI-guided workflows into a single development cycle. By focusing on iteration speed and experimental readouts, the companies are targeting one of the practical constraints that can slow progress in AI-enabled drug discovery programs.
📌 Our Take: Faster lab-to-model feedback could become the defining advantage in the next phase of AI-driven biologics development.